CD47 and neoplasm: Therefore, we further established the LLC bilateral subcutaneous tumor model to evaluate the anti-tumor effects of Vpr peptide combined with SIRPαFc, a fusion protein for CD47 blockade therapy [60,61,62,63,64] (Figure 8A).